tert-butyl {5-chloro-2-hydroxy-4-[(4-methoxybenzyl)oxy]phenyl}carbamate | 1003567-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl {5-chloro-2-hydroxy-4-[(4-methoxybenzyl)oxy]phenyl}carbamate
• 英文别名: tert-butyl N-[5-chloro-2-hydroxy-4-[(4-methoxyphenyl)methoxy]phenyl]carbamate
• CAS: 1003567-38-1
• 化学式: C₁₉H₂₂ClNO₅
• 分子量: 379.84
• InChiKey: FOGLZWAHERKUHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  77
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl {5-chloro-2-hydroxy-4-[(4-methoxybenzyl)oxy]phenyl}carbamate 、 (S)-(+)- 间硝基苯磺酸缩水甘油酯 在 caesium carbonate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 18.0h， 以99%的产率得到tert-butyl {5-chloro-4-[(4-methoxybenzyl)oxy]-2-[(2S)-oxiran-2-ylmethoxy]phenyl}carbamate
  参考文献：
  名称：

  WO2008/10765

  摘要：

  公开号：

文献信息

• Novel Compounds 243
  申请人：Gibson Scott

  公开号：US20080167332A1

  公开（公告）日：2008-07-10

  Compounds of formula (I) wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

  本发明描述了式(I)的化合物，其中R1、R3、R4、R5、R6、R7和R10如说明书中所定义。本发明还涉及包含所述化合物的制药组合物以及所述化合物在治疗中的使用。本发明还涉及制备所述化合物的过程以及制备所述化合物有用的新中间体。此外，本发明还涉及新化合物的盐和多晶形式，以及其制备。
• Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity
  申请人：Eriksson Tomas

  公开号：US20090176815A1

  公开（公告）日：2009-07-09

  Compounds of formula (I) wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

  本发明描述了式(I)的化合物，其中R1、R3、R4、R5、R6、R7和R10如规范中所定义。本发明还涉及包含所述化合物的制药组合物以及在治疗中使用所述化合物的用途。本发明还涉及制备所述化合物的过程以及在制备中有用的新中间体。此外，本发明还涉及所述新化合物的盐和多晶形式以及其制备。
• NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP2069355A1

  公开（公告）日：2009-06-17
• [EN] NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：ASTRAZENECA AB

  公开号：WO2008010765A1

  公开（公告）日：2008-01-24

  [EN] Compounds of formula (I) wherein R¹, R³, R⁴, R⁵, R⁶, R⁷, and R¹⁰ are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.
  [FR] L'invention concerne des composés de formule (I) dans laquelle R¹, R³, R⁴, R⁵, R⁶, R⁷ et R¹⁰ sont tels que définis dans la description. La présente invention concerne également une composition pharmaceutique comprenant ces composés, ainsi que l'utilisation de ces composés en thérapie. La présente invention concerne, en outre, des procédés de préparation de ces composés et de nouveaux intermédiaires utiles dans leur préparation. De plus, l'invention concerne des sels et des formes polymorphes des nouveaux composés, ainsi que leur préparation.
• WO2008/10765
  申请人：——

  公开号：——

  公开（公告）日：——